GBLX
vs
S&P 500
GBLX
S&P 500
Over the past 12 months, GBLX has underperformed S&P 500, delivering a return of -92% compared to the S&P 500's +15% growth.
Stocks Performance
GBLX vs S&P 500
Performance Gap
GBLX vs S&P 500
Performance By Year
GBLX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
GB Sciences Inc
Glance View
GB Sciences, Inc. is a phytomedical research and biopharmaceutical drug development company, which focus on treating diseases with cannabinoid medicines. The company is headquartered in Las Vegas, Nevada and currently employs 16 full-time employees. The company went IPO on 2003-12-22. The firm is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. The company offers artificial intelligence (AI) accelerated drug discovery platform, PhAROS, Phytomedical Analytics for Research Optimization at Scale. The PhAROS platform is a science gateway and virtual research environment for drug discovery. Through its subsidiary, GBS Global Biopharma, Inc., the company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. The firm's list of subsidiaries includes GBS Global Biopharma, Inc., ECRX, Inc., The PhAROS Institute, LLC, GB Sciences Texas, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC and GB Sciences Nopah, LLC.
